Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDQuarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
---|---|---|---|---|
Q1 2025 | 2 | -$0.14 | -$0.10 | -$0.12 |
Q2 2025 | 1 | -$0.28 | -$0.00 | -$0.15 |
Q3 2025 | 1 | -$0.30 | -$0.00 | -$0.16 |
Q4 2025 | 1 | -$0.28 | -$0.00 | -$0.15 |
Q1 2026 | 1 | -$0.24 | -$0.00 | -$0.13 |
Q2 2026 | 1 | -$0.24 | -$0.00 | -$0.13 |
Q3 2026 | 1 | -$0.25 | -$0.00 | -$0.13 |
Q4 2026 | 1 | -$0.24 | -$0.00 | -$0.13 |
Silence Therapeutics plc last posted its earnings results on Thursday, February 27th, 2025. The company reported $0.27 earnings per share for the quarter, topping analysts' consensus estimates of $-0.45 by $0.72. The company had revenue of 1.14 M for the quarter and had revenue of 43.26 M for the year. Silence Therapeutics plc has generated $0 earnings per share over the last year ($-0.0003 diluted earnings per share) and currently has a price-to-earnings ratio of -2.61. Silence Therapeutics plc has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, March 12th, 2025 based on prior year's report dates.
Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
---|---|---|---|---|---|---|
11/14/2024 | Q3 2024 | -$0.42 | -$0.19 | 0.23 | $4.37 M | $1.14 M |
08/15/2024 | Q2 2024 | -$0.32 | -$0.11 | 0.21 | $9.21 M | $598,000 |
03/30/2024 | Q1 2024 | N/A | -$0.01 | N/A | N/A | $12.41 M |
03/13/2024 | Q4 2023 | -$0.25 | -$0.12 | 0.13 | N/A | $2.10 M |
09/29/2023 | Q3 2023 | N/A | -$0.07 | N/A | $2.41 M | $2.80 M |
06/30/2023 | Q2 2023 | N/A | -$0.10 | N/A | $3.06 M | $9.10 M |
03/31/2023 | Q1 2023 | N/A | -$0.09 | N/A | N/A | $11.37 M |
03/15/2023 | Q4 2022 | $0.45 | -$0.14 | -0.59 | N/A | $4.77 M |
09/29/2022 | Q3 2022 | N/A | -$0.07 | N/A | N/A | $3.37 M |
06/29/2022 | Q2 2022 | N/A | -$0.13 | N/A | N/A | $3.64 M |
03/30/2022 | Q1 2022 | N/A | -$0.09 | N/A | N/A | $5.72 M |
03/17/2022 | Q4 2021 | -$0.62 | -$0.11 | 0.51 | N/A | $3.41 M |
09/29/2021 | Q3 2021 | N/A | -$0.11 | N/A | N/A | $3.16 M |
06/30/2021 | Q2 2021 | N/A | -$0.13 | N/A | $2.38 M | $2.70 M |
03/31/2021 | Q1 2021 | N/A | -$0.10 | N/A | N/A | $3.14 M |
03/30/2021 | Q4 2020 | N/A | -$0.02 | N/A | N/A | $-842,000 |
09/29/2020 | Q3 2020 | N/A | -$0.11 | N/A | N/A | $1.99 M |
06/29/2020 | Q2 2020 | N/A | -$0.07 | N/A | N/A | $573,000 |
03/30/2020 | Q1 2020 | N/A | -$0.07 | N/A | N/A | $573,000 |
12/30/2019 | Q4 2019 | N/A | -$0.07 | N/A | N/A | $122,000 |
Silence Therapeutics plc has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, March 12th, 2025 based offlast year's report dates.
In the previous quarter, Silence Therapeutics plc (:SLN) reported $0.27 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.45 by $0.72.
The conference call for Silence Therapeutics plc's latest earnings report can be listened to online.
The conference call transcript for Silence Therapeutics plc's latest earnings report can be read online.
Silence Therapeutics plc (:SLN) has a recorded annual revenue of $43.26 M.
Silence Therapeutics plc (:SLN) has a recorded net income of $-45,309,000.Silence Therapeutics plc has generated $-0.0003 earnings per share over the last four quarters.
Silence Therapeutics plc (:SLN) has a price-to-earnings ratio of -2.61 and price/earnings-to-growth ratio is 0.08.
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTED